These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2024 related articles for article (PubMed ID: 7680764)
1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764 [TBL] [Abstract][Full Text] [Related]
2. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652 [TBL] [Abstract][Full Text] [Related]
3. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619 [TBL] [Abstract][Full Text] [Related]
4. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819 [TBL] [Abstract][Full Text] [Related]
5. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma]. Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405 [TBL] [Abstract][Full Text] [Related]
7. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442 [TBL] [Abstract][Full Text] [Related]
8. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577 [TBL] [Abstract][Full Text] [Related]
10. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study. Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168 [TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype. Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583 [TBL] [Abstract][Full Text] [Related]
12. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406 [TBL] [Abstract][Full Text] [Related]
13. [ProMACE-MOPP vs. ProMACE-CytaBOM polychemotherapies in the treatment of large-cell and unclassifiable non-Hodgkin's lymphomas]. Pieresca C; Gobbi PG; Bertoloni D; Grignani G; Rossi A; Legnani MC; Giordano M Ann Ital Med Int; 1991; 6(3):267-72. PubMed ID: 1723289 [TBL] [Abstract][Full Text] [Related]
14. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Kaplan LD; Straus DJ; Testa MA; Von Roenn J; Dezube BJ; Cooley TP; Herndier B; Northfelt DW; Huang J; Tulpule A; Levine AM N Engl J Med; 1997 Jun; 336(23):1641-8. PubMed ID: 9171066 [TBL] [Abstract][Full Text] [Related]
15. [CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas]. Avilés A; Huerta J; Guzmán R; Zepeda G; Díaz-Maqueo JC Rev Invest Clin; 1990; 42(4):271-6. PubMed ID: 1708910 [TBL] [Abstract][Full Text] [Related]
16. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148 [TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. Miller TP; Dahlberg S; Cassady JR; Adelstein DJ; Spier CM; Grogan TM; LeBlanc M; Carlin S; Chase E; Fisher RI N Engl J Med; 1998 Jul; 339(1):21-6. PubMed ID: 9647875 [TBL] [Abstract][Full Text] [Related]
19. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Guglielmi C; Gherlinzoni F; Amadori S; Mazza P; Mantovani L; Lauria F; Martelli M; Zinzani PL; Greco V; Poletti G Haematologica; 1989; 74(6):563-9. PubMed ID: 2483401 [TBL] [Abstract][Full Text] [Related]
20. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma. Armitage JO Ann Oncol; 1991 Jan; 2 Suppl 1():37-41. PubMed ID: 1710488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]